






CANCER DRUG DISCOVERY AND DEVELOPMENT:

BRIDGING ACADEMIC AND INDUSTRY PARTNERSHIPS
SPRING SYMPOSIUM

2007 HOLLINGS
CANCER CENTER



THE SANCTUARY,
KIAWAH ISLAND,
SOUTH CAROLINA

MARCH 23-24, 2007



2007 HOLLINGS CANCER CENTER SPRING SYMPOSIUM

CANCER DRUG DISCOVERY AND DEVELOPMENT: BRIDGING ACADEMIC AND INDUSTRY PARTNERSHIPS

Friday – Saturday, March 23-24, 2007

The Sanctuary, Kiawah Island, South Carolina

Advanced Registration Deadline: March 1, 2007

Symposium Director: Kenneth D. Tew, Ph.D., D. Sc.

Chair and Professor, Cell and Molecular Pharmacology,

John C. West Chair of Cancer Research

Medical University of South Carolina

INTRODUCTION

The 2007 Hollings Cancer Center Spring Symposium will focus on the science, clinical testing and business aspects underlying the development of novel cancer therapeutics. The pharmaceutical sector, large and small, has a burgeoning pipeline of cancer drugs, and targeted therapies are now focal endpoints for many types of cancer. The intent of this Symposium is to foster more in-depth dialogue of how both the academic institutions of South Carolina and the pharmaceutical sector can expedite the drug discovery process and subsequent testing via clinical trials. Sessions will include prominent, expert speakers who are leaders in the drug discovery/development field. There will be six interrelated thematic sessions with presentations and much time for discussion. This meeting will appeal to basic scientists, translational and clinical investigators, clinicians, laboratory and clinical trainees, biotechnology company scientists and venture capital representatives. Please join us in Kiawah.

SYMPOSIUM REGISTRATION



Registration for the conference can be completed by going online to <http://hcc.musc.edu/research/spring/> or contacting the Hollings Cancer Center directly at 843-792-0055.

Registration is \$50.00 but will be waived if registered by March 1, 2007. Only cash or checks will be accepted and should be made payable to MUSC Foundation. Registration fees will be collected at the Symposium registration table. Registered participants will be provided admission to all Symposium sessions, continental breakfast and lunch on both Friday and Saturday as well as dinner on Friday evening. There is a spouse/guest fee of \$25 for the Friday evening dinner; children are free.

CALL FOR ABSTRACTS

Participants are encouraged to submit scientific abstracts related to drug discovery/drug development. These will be collated in a booklet and distributed at the conference, and selected abstracts will be presented in poster format. The deadline for abstract submissions will be February 28, 2007.

Abstract submissions should include Project Title, PI and Collaborator Names, Institution/Department, phone and email of PI, funding support of project if appropriate, and description of project in 250 words or less. Abstracts should be submitted electronically in Microsoft Word to Peggy Boehrig at boehrigp@muscedu.



SYMPOSIUM SCHEDULE

FRIDAY, MARCH 23

7:00 – 7:45 AM

Continental Breakfast

7:45 – 8:00 AM

INTRODUCTION

Andrew S. Kraft, M.D., Director, Hollings Cancer Center; Professor, Medicine and William H. Folk, M.D., Chair in Experimental Therapeutics

8:00 – 10:00 AM

SESSION 1: DRUG TARGETS: SIGNALING KINASES AND PHOSPHATASES

Co-Chairs: **Michael E. Pierce**, Senior Director, Pharmaceutical Process Development, Roche Carolina, Inc., and **Stephen M. Lanier, Ph.D.**, Associate Provost for Research, MUSC

Neil W. Gibson, Ph.D., Chief Scientific Officer, OSI Pharmaceuticals

Lessons Learned from the Development of the EGFR Inhibitor Erlotinib in NSCLC and Pancreatic Cancer

John S. Lazo, Ph.D., Chair, Pharmacology, University of Pittsburgh School of Medicine; Co-Director, Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute

Challenges and Opportunities in Targeting Protein Tyrosinephosphatases for Cancer Therapy

Allen J. Lovey, M.S., Senior Principal Scientist, Discovery Chemistry-Oncology, Hoffmann-La Roche, Inc.

The Discovery of a Novel CDK Inhibitor: A Successful Paradigm Shift

Emerging Targets at MUSC and USC

Steven A. Rosenzweig, Ph.D., Professor, Cell and Molecular Pharmacology, MUSC

Targeting the IGF System

Bryan P. Toole, Ph.D., Professor, Cell Biology & Anatomy, MUSC

Hyaluronan, RTKs and Cancer Stem Cells

Campbell McInnes, Ph.D., Assistant Professor, Medicinal Chemistry, University of South Carolina

Polo Box Domain of Plk1

10:00 – 10:30 AM

Break

10:30 AM – 12:30 PM

SESSION 2: DRUG TARGETS: REDOX PLATFORM

Co-Chairs: **Rick G. Schnellmann, Ph.D.**, Chair and Professor, Pharmaceutical Sciences, MUSC, and **Kenneth D. Tew, Ph.D., D.Sc.**, Chair and Professor, Cell and Molecular Pharmacology, John C. West Chair of Cancer Research, MUSC

Christopher J. Pazoles, Ph.D., Vice President, Research & Development, Novelos Therapeutics, Inc.

NOV-002: Oxidized Glutathione as a Novel Platform for Cancer Therapeutics

Michael M. Wick, M.D., Ph.D., Chairman and Chief Executive Officer, Telik Inc.

TLK199, a Novel Non-Oxidizable Glutathione Inhibitor of GST P1-1: Effects Upon Growth and Differentiation of Hematopoietic Cells

D. Lynn Kirkpatrick, Ph.D., Chief Executive Officer, ProLx Inc.

Redox Cancer Drugs in the Lab and the Clinic

Emerging Targets at MUSC

Danyelle M. Townsend, Ph.D., Assistant Professor, Pharmaceutics Sciences, MUSC

Protein Disulfide Isomerase and the Unfolded Protein Response

Jennifer S. Isaacs, Ph.D., Assistant Professor, Cell and Molecular Pharmacology, MUSC

Heat Shock Proteins

Carola A. Neumann, M.D., Assistant Professor, Cell and Molecular Pharmacology, MUSC

Peroxiredoxins

12:30 PM

Lunch

1:30 – 4:30 PM

Afternoon free

4:30 – 5:45 PM

SESSION 3: OPTIMIZING THE ACADEMIC/INDUSTRY INTERFACE

Chair: **Richard Kinney**, Retired Vice President for Public Affairs, Schering-Plough Corporation; Member, Hollings Cancer Center Advisory Board

Robert A. Kramer, Ph.D., Vice President, Oncology and Immunology Discovery Biology, Bristol-Myers Squibb Pharmaceutical Research Institute

Industry Academia Relationships in the Current Era: Example, Dasatinib

Charles D. Smith, Ph.D., Professor and Charles and Carol Cooper Chair in Pharmacy, Pharmaceutical Sciences, MUSC

Using the SBIR/STTR Program to Bootstrap Academic Spin-out Companies

5:45 – 7:00 PM

ROUND TABLE DISCUSSION FROM HOLLINGS CANCER CENTER/MUSC PERSPECTIVES

Moderator: **Raymond S. Greenberg, M.D., Ph.D.**, President, MUSC

Panel to include:

First Lady Jenny Sanford

The Honorable Joe E. Taylor,

Secretary of Commerce for South Carolina

The Honorable Joseph P. Riley, Jr.,

Mayor of Charleston

John R. Raymond, M.D., MUSC Vice President for Academic Affairs and Provost



Jerry G. Reves, M.D., MUSC Vice President for Medical Affairs and Dean, College of Medicine

Stephen M. Lanier, Ph.D., Associate Provost for Research, MUSC

W. C. "Chip" Hood, Jr., J.D., Executive Director, MUSC Foundation for Research Development

7:00 – 10:00 PM

Evening reception and barbeque for all registered attendees



SATURDAY, MARCH 24

7:00 – 8:00 AM

Continental Breakfast

8:00 – 10:00 AM

**SESSION 4: DRUG TARGETS:
BIOLOGICS AND GENE THERAPY**

Co-Chairs: **Yusuf A. Hannun, M.D.,**

Ralph H. Hirschmann Professor and Chair,
Biochemistry and Molecular Biology and

James S. Norris, Ph.D., Professor and Chair,
Microbiology and Immunology, MUSC

John J. Nemunaitis, M.D., Executive Director,
Mary Crowley Medical Research Center,
Dallas, Texas

Clinical Update of Adp53

Noriyuki Kasahara, M.D., Ph.D., Associate
Professor, Medicine; Director, Gene Therapy,
University of California, Los Angeles

Lentiviral Vectors in Human Gene Therapy

Larry Kauvar, Ph.D., Founder and
Vice Chairman, Trellis Bioscience

**Better Therapeutic Antibodies from
Novel Screening Technology**

Emerging Targets at MUSC

James S. Norris, Ph.D., Professor and Chair,
Microbiology and Immunology, MUSC

Acid Ceramidase as a Drug Target in Cancer

Christina Voelkel-Johnson, Ph.D.,

Assistant Professor, Microbiology and
Immunology, MUSC

Elongation Factor 2: Control of Apoptosis

Besim Ogretmen, Ph.D., Associate Professor,
Biochemistry and Molecular Biology, MUSC

**Lipid-protein Interaction between
Ceramide and the Inhibitor 2 of PP2A:
Regulation of c-Myc**

10:00 – 10:30 AM

Break

10:30 – 11:30 AM

**SESSION 5: NON-US
PERSPECTIVES ON ACADEMIC/
INDUSTRY LIAISONS**

Co-Chairs: **Daniel J. Fernandes, Ph.D., Sc.D.,**

Professor, Biochemistry and Molecular
Biology, MUSC, and **Harris Pastides, Ph.D.,**

Vice President, Research, USC

Peter van Bladeren, Ph.D., Director, Nestle
Research Center, Switzerland

**Developing Foods with Health Benefits
through Partnerships with Academia**

Nigel Courtenay-Luck, Ph.D., Chief Scientific
Officer, Antisoma Limited, London, England
**AS1411: The First Aptamer in Phase I Clinical
Oncology Trials**

Alfred M. Ajami, Ph.D. Chief Scientific Officer,
Xanthus Pharmaceuticals, Cambridge/Montreal
**Symadex: The Chemical Biology of an
Unprecedented Kinase Inhibitor**

11:30 AM – 1:30 PM
**SESSION 6: CLINICAL AND
REGULATORY ISSUES IN
DRUG DEVELOPMENT**

Box lunches will be available during this session

Co-Chairs: **Allen I. Oliff, M.D.,** Senior Vice
President, Molecular Research, GlaxoSmithKline
Pharmaceuticals; Member, Hollings Cancer
Center Advisory Board and **Andrew S. Kraft,
M.D.,** Director, Hollings Cancer Center and
William H. Folk, M.D. Chair in Experimental
Oncology, MUSC

Peter J. Houghton, Ph.D., ALSAC Chair
of Pharmacology; Professor, Molecular
Pharmacology, St. Jude Children's
Research Hospital, Memphis, TN
**The Pediatric Preclinical Testing Program:
A Paradigm for Anticancer Drug Discovery
and Development**

Michael J. Morin, Ph.D., Vice President,
Antibacterials, Immunology and Cancer Drug
Discovery, Pfizer Groton/New London Labs
**Putting It All Together - It Takes a Village
to Raise a Drug**



Garth Powis, and D.Phil., Director, Basic
Research; Professor, Pathology, Pharmacology
and Molecular and Cell Biology,
M. D. Anderson Cancer Center
**Personalized Medicine for Cancer -
How Do We Make it a Reality?**

Emerging Targets at MUSC and USC
Michael J. Wargovich, Ph.D., Professor,
Cell and Molecular Pharmacology, MUSC
Chemopreventive Agents

Craig C. Beeson, Ph.D., Associate Professor,
Pharmaceutical Sciences, MUSC
HIF and Tumor Specific Mitochondrial Targets

Franklin G. Berger, Ph.D., George H. Bunch
Professor, Biological Sciences, and Director,
Center for Colon Cancer Research, USC
Targeting the Polyamine Catabolic Pathway

**Afternoon: Symposium participants are
welcome to enjoy the afternoon at Kiawah.**

6:30 PM

Evening reception (invitation only)

7:30 PM


Dinner (invitation only)

Speakers:

**South Carolina Governor Mark Sanford
Reasons to Work and Live in South Carolina**

Kenneth D. Tew, Ph.D., D.Sc., Chair,
and Professor, Cell and Molecular
Pharmacology, John C. West Chair of
Cancer Research, MUSC

**South Carolina Centers of Excellence:
Adventures in Drug Targets**



ACCOMMODATIONS

THE SANCTUARY, KIAWAH ISLAND, SOUTH CAROLINA

WWW.THESANCTUARY.COM



Along the pristine shores of Kiawah Island, South Carolina, The Sanctuary at Kiawah Island captures the spirit and charm of southern hospitality. This exquisite luxury hotel, just 30 minutes from downtown Charleston, radiates with ultimate oceanfront living and leisure. You'll be presented with a superb complement of guestrooms and the privilege of golfing five championship courses, basking in a unique nature-based spa and playing at two world-class tennis clubs. The Sanctuary also has two elegant restaurants, fitness room, indoor pool and Jacuzzi, martini bar and oceanfront poolside grill.

A block of rooms with ocean views has been reserved at The Sanctuary for this Symposium. To ensure a guest room at the established conference rate (\$395 per night) call the resort toll free 1-800-654-2924. Identify yourself as a participant in the Hollings Cancer Center Drug Discovery/Development Symposium. Kiawah has extended the group rate for one day prior and one day after the official meeting dates. Reservations received after March 1, 2007, will be accommodated on a space and rate availability only. All Sanctuary rooms are subject to a \$20 service fee per night, which includes on-island transportation to all resort venues via the existing fleet of resort vehicles and all local and 800 telephone access. Services guests receive at no charge are high-speed Internet access, golf club storage, access to fitness center, coffee in the lobby from 6:30-7:30 a.m., self parking, beach services and overnight shoe shine. Rates are presently subject to a 6.5% South Carolina state tax and a total of 5% local taxes. The maximum occupancy at The Sanctuary is two adults per bedroom.

TRAVEL DIRECTIONS

DRIVING:



From the North: From I-95 South, approach the Charleston area on I-26 East and then onto I-526 West. Follow I-526 to Highway 17 South, travel approximately five miles and turn left onto Main Road. Follow the signs to Kiawah Island.

From the South: Follow I-95 North to US-17 North (Charleston - Exit 33). Travel 52 miles on US-17, then turn right onto Main Road. Follow the signs to Kiawah Island.

FROM THE AIRPORT:

Upon exiting the airport, turn right onto I-526 West toward Savannah. I-526 will end in approximately six miles. Turn right onto US-17 South. Travel about five miles and turn left onto Main Road. Follow the signs to Kiawah Island. Charleston International Airport is only 45 minutes from Kiawah, while the area's executive airport — perfect for private and corporate jets — is only 15 minutes away.

If you would like to make pre-arrangements for transportation from the airport to Kiawah, we recommend contacting Mitch's Limo Service at 843-559-6902 or 843-270-6902. To guarantee this transportation availability, it is recommended that you call two weeks in advance.



SYMPOSIUM CONTACT:

PEGGY BOEHRIG

MEDICAL UNIVERSITY OF SOUTH CAROLINA

Hollings Cancer Center

Phone: 843-792-6659

Fax: 843-792-4233

E-mail: boehrigp@musc.edu



MUSC
HOLLINGS CANCER CENTER